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Background: Chlamydia trachomatis is a pathogen of worldwide importance, causing more than 100 million cases
of sexually transmitted infections annually. Whole-genome sequencing is a powerful high resolution tool that can
be used to generate accurate data on bacterial population structure, phylogeography and mutations associated
with antimicrobial resistance. The objective of this study was to perform whole-genome enrichment and sequencing
of C. trachomatis directly from clinical samples.
Methods: C. trachomatis positive samples comprising seven vaginal swabs and three urine samples were sequenced
without prior in vitro culture in addition to nine cultured C. trachomatis samples, representing different serovars. A custom
capture RNA bait set, that captures all known diversity amongst C. trachomatis genomes, was used in a whole-genome
enrichment step during library preparation to enrich for C. trachomatis DNA. All samples were sequenced on the MiSeq
platform.
Results: Full length C. trachomatis genomes (>95-100% coverage of a reference genome) were successfully generated for
eight of ten clinical samples and for all cultured samples. The proportion of reads mapping to C. trachomatis and the
mean read depth across each genome were strongly linked to the number of bacterial copies within the original sample.
Phylogenetic analysis confirmed the known population structure and the data showed potential for identification of
minority variants and mutations associated with antimicrobial resistance. The sensitivity of the method was >10-fold
higher than other reported methodologies.
Conclusions: The combination of whole-genome enrichment and deep sequencing has proven to be a non-mutagenic
approach, capturing all known variation found within C. trachomatis genomes. The method is a consistent and sensitive
tool that enables rapid whole-genome sequencing of C. trachomatis directly from clinical samples and has the potential
to be adapted to other pathogens with a similar clonal nature.
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Chlamydia trachomatis is the most common bacterial
agent in sexually transmitted infections (STI), globally ac-
counting for more than 100 million infections [1,2]. This
bacterium (serovar A-C) causes the blinding disease,
trachoma, which affects millions of people worldwide* Correspondence: m.christiansen@ucl.ac.uk
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article, unless otherwise stated.[3,4]. The morbidity from C. trachomatis infections places
a heavy economic burden on society [5,6].
C. trachomatis is an obligate intracellular pathogen
with a two-phase developmental cycle that consists of
infectious elementary bodies (EBs) and replicating re-
ticulate bodies (RBs). EBs are taken up by host cells into
an inclusion vacuole in which they differentiate into rep-
licating RBs. The cycle ends when the RBs differentiate
back into EBs and are released from the host cell by lysis
or egress of inclusions [7,8]. EBs have traditionally beenntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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shown metabolic activity in EBs when cultured in a la-
boratory cell-free system [9].
C. trachomatis strains are classified into two biovars:
the ocular/urogenital biovar and the lymphogranuloma
venereum (LGV) biovar (for review) [10]. The two bio-
vars can be subdivided into 15–19 different serovars.
Further genotypic classification is based on nucleotide
sequencing of the ompA gene, which encodes the major
outer membrane protein and is the target of serotype
classification. The ocular/urogenital biovar consists of
the ocular serovars A-C and the urogenital serovars D-
K, all of which are usually confined to mucosal epithelia
whereas the LGV biovar, consisting of serotypes L1-L3,
is more invasive and can disseminate to other tissues
and the draining lymphatic system. It has previously
been demonstrated that genotyping of the ompA gene is
insufficient for exploring C. trachomatis population struc-
ture and performing molecular epidemiological studies on
transmission as this region undergoes high levels of re-
combination [11]. Also, variation within the ompA gene
differs among serovars and sexual networks can be pre-
dominated by a single serovar, making strain distribution
and evolutionary studies impractical [12,13]. In this con-
text, whole genome sequencing (WGS) has been used to
generate accurate data on bacterial population structure
and phylogeography [14]. In addition whole genome se-
quencing can also facilitate the identification of mutations
associated with antimicrobial resistance [15,16].
Clinical samples often contain low numbers of patho-
gens and to obtain sufficient material for WGS of C. tra-
chomatis, in vitro culture is usually required. However,
as C. trachomatis is an obligate intracellular pathogen it
is labour intensive to grow in vitro [17]. For this reason,
methods that allow sequencing directly from C. tracho-
matis positive samples are particularly attractive. An ex-
ample of this was recently described [18]; the approach
was based on an antibody-based enrichment step target-
ing intact C. trachomatis cells followed by whole gen-
ome amplification of the total amount of DNA within
the sample. The method proved useful for sequencing C.
trachomatis from complex clinical samples but required
in excess of 1,500,000 genome copies per microliter, fol-
lowing whole genome amplification, and sequencing on
an Illumina HiSeq to generate sufficient numbers of reads
for C. trachomatis genome mapping. Overall this ap-
proach showed only a 15-30% success rate, which under-
lines the need for a more reliable methodology.
It has previously been shown that the SureSelectXT
Target-Enrichment protocol (Agilent Technologies), which
uses custom designed 120-mer RNA oligonucleotides that
span the entire genome, can recover (by hybridisation) low
copy number herpesviruses from clinical samples with suf-
ficiently high sensitivity and specificity to enable ultra-deepwhole genome sequencing [19,20]. In this study we used
the SureSelectXT Target-Enrichment approach to improve
the sensitivity of C. trachomatis whole genome sequencing
from clinical specimens. This method offers the opportun-
ity for gaining a wider understanding of the C. trachomatis
population structures, transmission patterns and of the
evolution of antimicrobial resistance.
Methods
Ethics statement
The clinical samples were obtained independently from
patients with confirmed genital Chlamydia trachomatis
infections. These were diagnostics samples collected as
part of the standard clinical procedure at Barts Health
NHS Trust and were obtained by the UCL Infection DNA
Bank for use in this study. All samples were supplied to the
study in an anonymised form and the use of these speci-
mens for research was approved by the NRES Committee
London – Fulham (REC reference: 12/LO/1089).
C. trachomatis culture samples
Nine isolates were obtained from a sample archive at
University College London Hospital (UCLH). These cul-
tured isolates were used to optimise the bait set. Origin-
ally these C. trachomatis samples were obtained from
clinical specimens and isolated via several embryonated
chick egg passages as described previously [21]. The sam-
ples were stored at −80°C after original isolation. After
several years of storage the samples were propagated in
cycloheximide treated McCoy cells (without antibiotics) in
shell vials and then inoculated on to 25 cm2 tissue culture
flasks. After the second round of culture the samples were
harvested, centrifuged and re-suspended in Minimum Es-
sential Medium (MEM) supplemented with Hank’s bal-
anced salt solution, L glutamine and dimethyl sulfoxide
(DMSO) as a cryo-preservative and stored at −80°C until
DNA extraction.
For DNA extraction, the samples were thawed and the
cells were pelleted, re-suspended in 100 μl proteinase K
solution and incubated at 60°C for 1 hour. DNA was ex-
tracted from the samples using the Promega Wizard
Genomic DNA Purification Kit. C. trachomatis DNA
within each sample was quantified by qPCR targeting
the C. trachomatis plasmid and the genomic omcB gene,
using a dilution series of plasmid containing the target
sequence as standard. Human RNase-P was used as an
endogenous control.
C. trachomatis clinical samples
Ten C. trachomatis diagnostic positive samples (tested
using the Viper platform, BD Diagnostics) were collected
at Barts Health NHS Trust: seven vaginal swabs and
three urine samples. The samples were stored at −80°C
until DNA extraction. DNA was extracted directly from
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QIAamp DNA Mini Kit. C. trachomatis DNA within
each sample was quantified by qPCR, targeting the C.
trachomatis plasmid and the genomic omcB gene. Hu-
man RNase-P was used as an endogenous control [22].
SureSelectXT Target Enrichment: RNA baits design
The 120-mer RNA baits spanning the length of the po-
sitive strand of 74 GenBank C. trachomatis reference
genomes were designed using an in-house PERL script
developed by the PATHSEEK consortium. The specifi-
city of the baits was verified by BLASTn searches against
the Human Genomic + Transcript database. The custom
designed C. trachomatis bait library was uploaded to
SureDesign and synthesised by Agilent Technologies.
SureSelectXT Target Enrichment: Library preparation,
hybridisation and enrichment
C. trachomatis DNA samples were quantified and carrier
human genomic DNA (Promega) was added to obtain a
total of 3 μg input for library preparation. To assess the
sensitivity of the whole-genome enrichment and sequen-
cing a dilution series of C. trachomatis DNA extracted
from culture was generated. One undiluted sample and
6 dilutions were generated with target input DNA (C.
trachomatis DNA) ranging from 3 μg to 0.01 ng. The di-
luted samples were bulked to 3 μg with human carrier
DNA, as before.
All DNA samples were sheared for 6x60 seconds using
a Covaris E210 (duty cycle 10%, intensity 5 and 200 cycles
per burst using frequency sweeping). End-repair, non-
templated addition of 3’ poly A, adapter ligation, hybrid-
isation, PCR and all post- reaction clean-up steps were
performed according to the SureSelectXT Illumina Paired-
End Sequencing Library protocol (V1.4.1 Sept 2012). All
recommended quality control steps were performed.
Illumina sequencing
Samples were multiplexed to combine either eight or ten
samples per run. Paired end sequencing was performed
on an Illumina MiSeq sequencing platform with a 300 bp
v2 reagent set. Base calling and sample demultiplexing
were generated as standard producing paired FASTQ files
for each sample. The cultured samples were sequenced in
a single run whereas the sequencing of the clinical sam-
ples was repeated to increase sequence depth.
Sequence data analysis
Genome mapping, assembly and finishing was per-
formed using CLC Genomics Workbench (version 6.5.0/
6.5.1) including the CLC Microbial Genome Finishing
Module (version 1.2.1/1.3.0) from Qiagen. For each data
set, all read-pairs were subject to quality control and
reads were quality trimmed based on the presence ofambiguous nucleotides using the default parameters
(Additional file 1). All remaining reads were mapped to
a C. trachomatis reference genome and consensus se-
quences extracted using default parameters. Samples
from the ocular/urogenital biovar (ten clinical samples
plus seven cultured samples) were aligned to C. trachoma-
tis isolate F/SW4 (GenBank accession no. NC_017951.1)
whereas samples from the LGV biovar (two cultured sam-
ples) were aligned to C. trachomatis L2/434/Bu reference
genome (GenBank accession no. AM884176). The uro-
genital strain F/SW4 has been used as reference in a
previous study where it was defined as a completed
high-quality reference [18] and was applied here due to
the urogenital nature, which is compatible with the
clinical sample set obtained from vaginal swabs (female
patients) and urine (male patients). When defining
mean read depth obtained from the C. trachomatis
from vaginal swabs, the duplicated rRNA regions were
masked as these regions were found to have a signifi-
cantly higher read depth compared to the rest of the C.
trachomatis genome (see coverage plot in Additional
file 1). For comparison, de novo assembly was also per-
formed for the clinical samples. All assemblies were
performed using CLC Genomics Workbench with de-
fault parameters. The Microbial Genome Finishing
Module was applied for de novo assembly in CLC
Genomics Workbench and mapping mode was set to
‘map reads back to contigs (slow). Following reference
based assembly, in silico genotyping was performed on the
ompA gene sequences obtained from the clinical sam-
ples. Consensus sequences were aligned with C. tracho-
matis whole genome sequences found in GenBank
using MAFFT (progressive approach) and the alignment
was visualised and manually corrected in MEGA
[23,24]. SNP differences between a cultured sample,
which was processed with and without whole-genome
enrichment, and the C. trachomatis isolate F/SW4
(GenBank accession no. NC_017951.1) were called with
Base-By-Base and SNPs found within coding regions
were visualised in a Circos-plot [25,26]. To assess any
potential differences associated with body compart-
ments, non-synonymous SNP difference between the
clinical consensus sequences and the reference (C. tra-
chomatis isolate F/SW4) were identified and visualized
in a Circos plot [26].
Mutations in the C. trachomatis genome associated
with antibiotic resistance were identified from the litera-
ture [16,27-33]. The mapping data from the clinical sam-
ples were assessed for these mutations.
For samples with high mean read depth, variants were
called using quality-based variant detection in CLC
Genomics Workbench with a minimum read depth of
40x, minimum average quality of 20, and minimum re-
quired variant count of 2 present on both the forward
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20-80% [20,34]. Variant sites with frequencies >5% were
inspected manually.
Phylogenetic reconstructions of the alignment data
were performed and neighbour-joining trees were gener-
ated using various models of evolution and a gamma cor-
rection for among-site variation with four rate categories
using MEGA [24]. The appropriate model of substitution
for generation of a maximum likelihood tree was identi-
fied using jModelTest and a maximum likelihood tree was
built using RAxML [35,36]. All trees were generated with
500 bootstrap replicates.
Recombination within the ompA gene was evaluated for
all the clinical samples using RAT, SBP and GARD [37,38].
The sequence data from the clinical samples was sub-
mitted to the National Center for Biotechnology Infor-
mation (NCBI) Sequence Read Archive (SRA) database
as Bioproject accession PRJNA262506.
Results
We sequenced 19 C. trachomatis samples, 9 from cul-
ture material and 10 directly from clinical material; three
urine samples and seven vaginal swabs.
To assess whether whole-genome enrichment increases
the number of reads mapping to the C. trachomatis
genome, extracted DNA from a single C. trachomatis cul-
tured sample was processed with and without whole-
genome enrichment prior to sequencing. All sequence
reads generated from the two libraries were mapped to a
reference genome (isolate F/SW4 GenBank accession
NC_017951.1) and the proportions of sequence reads map-
ping calculated. With whole-genome enrichment ~91% of
the sequence reads mapped to C. trachomatis whereas
without enrichment only ~7% of the sequence reads
mapped to C. trachomatis (Figure 1).Figure 1 The effect of whole-genome enrichment on the pro-
portion of reads mapping to C. trachomatis. The plot shows the
proportion of reads mapping to a C. trachomatis reference (F/SW4)
genome (% on-target reads) from a C. trachomatis cultured sample
that was processed with and without whole-genome enrichment.To evaluate if whole-genome enrichment introduces
any mutational bias, we compared the single nucleotide
polymorphic differences (SNPs – single nucleotide poly-
morphisms) found between the consensus sequence re-
covered from the sample processed with enrichment and
the consensus sequence recovered from the same sample
processed without and the reference strain (F/SW4).
Overall, no differences in the SNP profiles were found at
any position in the genome (both coding and non-
coding position) indicating that no mutational bias is in-
troduced by the whole-genome enrichment method used
(Figure 2 – for visualization only SNP differences within
coding regions are included in the circos plot).
The sensitivity of whole-genome enrichment of C. tracho-
matis DNA using SureSelectXT was evaluated using a series
of dilutions of C. trachomatis genomic DNA extracted from
a cultured sample. For each dilution human gDNA was
used to bulk the sample to contain 3 μg of starting material
prior to library preparation and sequencing. The proportion
of sequence reads mapping to a C. trachomatis reference
genome (F/SW4) was calculated for each dilution (Figure 3).
The data showed a saturation of ~90% on-target reads irre-
spective of the amount of input C. trachomatis DNA. From
approximately 48,000 C. trachomatis input genomes (based
on qPCR of the genomic omcB gene) we obtained close to
100% coverage of the reference genome with a mean read
depth of 20× and around 85% coverage of the reference
genome at a mean read depth of 100× (Figure 4). With a
ten-fold lower input (4,800 C. trachomatis genomes) we ob-
tained 98% coverage of the reference genome but with a
lower mean read depth (Figure 4). Using whole-genome en-
richment, a high proportion of sequence reads mapping to
C. trachomatis were obtained from all of the cultured sam-
ples and full length genomes were recovered, confirming
that our 120-mer RNA oligonucleotide set was capable of
enriching for strains from both biovars (Table 1).
Using whole-genome enrichment, C. trachomatis was
directly sequenced, without culture, from 10 clinical diag-
nostic samples containing between 33,000 to >6.8x106 C.
trachomatis genome copies per enrichment reaction. Each
sample was sequenced twice on the MiSeq platform and
the data were pooled to obtain between 1-50% sequence-
reads mapping to C. trachomatis. The sequence results are
summarised in Table 2. Eight of the ten clinical samples,
five vaginal swabs and three urine samples, generated >95%
coverage of the reference genome (Figure 5) with a mean
read depth between 6x - >400x (Table 2). For all 10 clinical
samples, we were able to map the full length C. trachomatis
plasmid with high mean read depth (Additional file 2). The
limit for generating full genomes from vaginal swabs was
551,820 C. trachomatis genomes (6,492 genome copies/μl)
in 100 μl DNA extract from 200 μl of the original sample,
corresponding to a PCR cycle threshold (Ct) of 27. The
limit for generating full genomes from urine samples was
Figure 2 SNP profiles in a C. trachomatis sample processed with and without whole-genome enrichment. The plot illustrates SNP profiles
in a cultured C. trachomatis sample processed with and without whole-genome enrichment compared to the GenBank reference strain isolate
F/SW4 (Accession no. NC_017951.1). The two outer tracks shown in green illustrate the open reading frames (ORFs) annotated in the GenBank
reference strain isolate F/SW4 with forward and reverse orientation. The red track shows the SNP differences found within coding regions
between the cultured C. trachomatis sample processed without whole-genome enrichment and the reference strain. The blue track shows the
SNP differences found within coding regions between the same cultured C. trachomatis sample processed with whole-genome enrichment and
the reference strain. The SNPs are called at the consensus level.
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100 μl DNA extract from 200 μl of the original sample, cor-
responding to a Ct of 31. Both reference based and de novo
assembly were performed with the read data from the se-
quenced clinical samples. The proportion of C. trachomatis
reads was sufficient for de novo assembly of samples CT-33Figure 3 Proportion of reads mapping to C. trachomatis
reference genome in relation to total C. trachomatis genome
copies input. Plot showing the relationship between the numbers
of input C. trachomatis genomes calculated and the proportion of
reads mapping to the C. trachomatis reference (F/SW4) genome
(% on-target reads).and CT-38, generating three and ten contigs respectively,
whereas the proportion of reads mapping to C. trachomatis
was suboptimal for de novo assembly of six samples (CT-
34, CT-36, CT-37, CT-40, CT-41, CT-42), generating be-
tween 46–297 contigs. The contigs generated by de novo
assembly from sample CT-33 were compared to the corre-
sponding consensus sequence extracted after reference
based mapping and showed 99.8-100% homology between
the sequences (data not shown).
Altogether 16 full consensus genomes (8 clinical samples
and 8 cultured samples) generated by reference based map-
ping were aligned against a collection of 23 C. trachomatis
genomes retrieved from GenBank. Phylogenetic analysis of
the aligned sequences by neighbour joining and maximum
likelihood showed identical topology. Two main clusters
were identified dividing the ompA serovars into the ocular/
urogenital and LGV biovars with the ocular/urogenital bio-
var subdivided into clades T1 and T2 (Figure 6) as previ-
ously shown [14]. The in silico ompA genotyping of sample
CT-37 was inconclusive. From a phylogenetic analysis with
the ompA gene sequence sample CT-37 was genotyped as
serovar C or K (data not shown) but from a phylogenetic
Figure 4 Coverage of reference genome and mean read depth in
relation to total C. trachomatis genome copies input. The plot
shows the amount of target DNA (C. trachomatis DNA) used in the
library preparations and the percentage coverage of the reference
genome obtained with the various target input. The bars (black, grey,
and white) illustrate the minimum mean read depth obtained from
each sample. The columns to the far left represent a sample which did
not undergo whole-genome enrichment during library preparation
(indicated with text – No enrichment).
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tered with the urogenital serovars (D-K) rather than the
ocular serovars (A-C) (Figure 6). The samples that se-
quenced successfully in this study were found throughout
the tree, confirming that our method can be used for
strains from both biovars. As has previously been described,
we found evidence of C. trachomatis recombination within
the ompA gene (Additional file 3) [14].
At least 34 substitutions (single or in combination) have
been reported in association with clinical and/or in vitro C.
trachomatis resistance to antimicrobial drugs (Additional
file 4). Although we had no data to suggest that any of the
clinical samples showed phenotypic antimicrobial resist-
ance, we examined consensus sequences for the presence
of reported mutations. Three mutations in the L22 gene
were identified in one sample (CT-36, Additional file 5).
L22 mutations have been associated with resistance to
macrolide antibiotics when they occur together with two
mutations within one of the 23S rRNA genes [33];Table 1 Overview of raw sequence data obtained from the cu
ID Sample type Genome copies
in 1–2 ml DNA
extract
Total input C.
trachomatis
genome copies
CT_10 Culture 2.3x109 362,346,600
CT_11 Culture 3.5x108 2,098,188,000
CT_12 Culture 8.1x109 683,544,000
CT_13 Culture 1.1x109 1,070,106,000
CT_14 Culture 1.8x109 8,421,480,000
CT_15 Culture 1.4x1010 5,587,859,200
CT_16 Culture 1.4x1010 1,563,216,000
CT_17 Culture 2.6x109 1224,048,000
All 8 samples were sequenced in a MiSeq run. The total input refers to the number
genotyping (ompA) was performed in the clinical laboratory.however, we found no mutations in the 23S rRNA genes
for this sample.
C. trachomatis in clinical samples is thought to con-
tain a mix of infectious EBs and replicating RBs. The lat-
ter is hypothesised to acquire mutations that confer
clinical resistance to antimicrobials [7]. Thus deep se-
quencing of antimicrobial resistant C. trachomatis may
reveal a heterogeneous population of resistant and sensi-
tive strains.
While none of our directly sequenced clinical strains
showed all mutations necessary for antimicrobial resistance,
we were able to evaluate baseline C. trachomatis heterogen-
eity in sample CT-33 which had a mean read depth of
>400×. Based on a previous study [20], we called only vari-
ants that were present at sites with a minimum read depth
of 40× and a minimum average base call quality of 20. A
variant count on a minimum of two reads was required
with the variant present in both forward and reverse reads
and a strand bias within a 20%-80% interval. We identified
variant sites to be present in ~0.08% of the genome with a
50:50 ratio of non-synonymous to synonymous mutations,
scattered throughout the genome and present for the
most part at <5% frequency (Additional file 6). Only six
single nucleotide variants causing non-synonymous sub-
stitutions were identified at frequencies >5% (Additional file
7). Two genes encoding hypothetical proteins, contained
one variant site each, at frequencies of around 10%. Two
other genes, encoding a histone H1-like protein HC2 and a
candidate inclusion membrane protein, contained two vari-
ant sites each at frequencies between 23-28%. The variant
sites within the gene encoding the histone H1-like protein
HC2 were found to be linked on the same sequence reads,
whereas the variant sites in the gene encoding the candi-
date inclusion membrane protein were not linked. Two fur-
ther clinical samples, CT-42 at the variant level and CT-34
at the consensus level, were found to contain the same
variant in the histone H1-like protein HC2 encoding-gene.
Three clinical samples, CT-34 at the variant level and CT-ltures C. trachomatis samples
Total
reads
Mapped
reads
Reads mapping
to C. trachomatis
Serovar/
Genotype
(ompA)
3450960 3058284 88.62% B
3847486 3455294 89.81% C
5055724 4632017 91.62% G
3923244 3512706 89.54% H
4814146 4524936 93.99% I
4572350 4242802 92.79% J
7734134 7240982 93.62% L1
6316494 5681915 89.95% L2
of C. trachomatis genome copies used as input in the library preparation. The
Table 2 Analysis of sequence data from DNA extracted directly from clinical C. trachomatis samples
ID Original
sample
type
Ct-value
(omcB)
Genome copies
in 100 μl DNA
extract
Total input
Chlamydia
genome copies
Total
reads
Mapped
reads
Reads
mapping to C.
trachomatis
Mean
read
depth
Coverage
of ref.
genome
Serovar/
Genotype
(ompA)
CT-33 Vaginal
swab
19.3 1.2x108 68,864,400 5,493,094 2,722,903 49.57% 410 99.9% D
CT-34 Vaginal
swab
26.5 1.0x106 868,530 8,016,738 105,030 1.31% 15.8 96.3% J
CT-35 Vaginal
swab
29 2.0x105 168,980 3,740,600 14,129 0.38% 2 59.1% -
CT-36 Vaginal
swab
26.5 1.0x106 864,705 3,731,308 195,331 5.23% 29.4 100.0% E
CT-37 Vaginal
swab
26.2 1.3x106 1,092,760 3,993,426 73,356 1.84% 11 98.4% C/K
CT-38 Urine 29.4 1.5x105 129,710 4,425,438 194,923 4.40% 29.4 99.9% Ia
CT-39 Vaginal
swab
30.6 7.0x104 59,755 4,454,502 2,975 0.07% 0.4 24.3% -
CT-40 Vaginal
swab
27.2 6.5x105 551,820 7,083,232 110,006 1.55% 16.5 98.8% Ia
CT-41 Urine 31.5 3.9x104 33,320 4,159,384 41,937 1.01% 6.3 95.2% E
CT-42 Urine 30.1 1.0x105 86,360 4,590,004 111,826 2.44% 16.9 99.9% G
All 10 samples were multiplexed and sequenced twice on a MiSeq in two separate runs, after which the data-sets were combined. Ct-value refers to a cycle threshold
obtained by qPCR and were defined in the clinical laboratory. Genome copies in 100 μl DNA extract from 200 μl original sample. The total input refers to the number of
C. trachomatis genome copies used as input in the library preparation. In silico genotyping was performed comparing the ompA gene sequence to other known serovars
found in GenBank.
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in the inclusion membrane protein encoding-gene. The
variable loci in the histone H1-like protein HC2 encoding-
gene and reference position 217,000 in the candidate inclu-
sion membrane protein encoding-gene (Additional file 7)
were found to be polymorphic in C. trachomatis GenBank
consensus sequences.
Twenty-one synonymous variant sites within coding
regions were identified at frequencies >5% in sample
CT-33 (data not shown). Of these, 18 were linked on the
same reads mapping within a 200 bp region in the tufA
gene, which encodes the translation elongation factor
Tu. Variant alleles within this region were present in all
seven vaginal swab samples and one of the urine samples
(CT-42). BLASTn analysis showed high homology be-
tween the vaginal tufA variant region and MobiluncusFigure 5 Coverage of reference genome - consensus sequences
obtained directly from clinical samples. The plot shows the
coverage of the reference genome (%) found when aligning the
consensus sequences generated from the eight clinical samples
that produced good genomic data.and Mycoplasma hominis, which can both be found within
the normal vaginal microbiota. The tufA variant region
identified in the urine sample (from male patient) showed
high homology to Lactobacillus casei, which is a bacterial
species present in human gut.
The non-synonymous SNP profiles obtained from the
vaginal swabs were compared to the profiles obtained
from the urine samples. No non-synonymous SNP pat-
terns were associated with body-compartment (Additional
file 8). The vaginal swab sample CT-36 and the urine sam-
ple CT-41 were found to contain fewer non-synonymous
SNPs compared to the F/SW4 reference, all clustering
within the ocular/urogenital T1 clade (Figure 6).
Discussion
We have shown that hybridising sequence libraries with
120-mer RNA oligonucleotides, designed specifically against
the C. trachomatis genome, increases the targeted genomic
DNA to a level that enable sequencing of full genomes
(>95-100% coverage of a reference genome) from clinical
specimens at >10-fold higher sensitivity than has previously
been reported [18]. The method does not require prior gen-
ome amplification and is therefore simpler and has been
proven more consistent in success than previous methods
[18,39]. Whole genome sequencing captures all of the gen-
omic information and has the potential to improve our un-
derstanding of C. trachomatis evolution. The widespread
use of antimicrobials and the global increase in antimicrobial
resistance among sexually transmitted bacterial infections
Figure 6 Neighbour-joining reconstruction of the phylogeny of C. trachomatis. The figure shows an un-rooted phylogenetic reconstruction
of the alignment data including 8 cultured and 8 clinical C. trachomatis samples sequenced in this study and 23 C. trachomatis genomes obtained
from GenBank. The Neighbour-joining tree was constructed with 500 bootstrap replicates using a Jukes Cantor model of evolution and gamma
correction for among-site rate variation with four rate categories. The gap/missing data was treated with a site coverage cut-off of 90%. The blue
clusters represent the ocular/urogenital biovar (dark blue T2 clade and light blue T1 clade) and the red cluster represents the LGV biovar. The
ocular serovars A-C cluster within the dark blue T2 clade. The samples sequenced in this study are highlighted in colours (blue and red) and the
GenBank strains are represented in black.
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http://www.biomedcentral.com/1471-2334/14/591[40] also argues for robust and reproducible sequence based
surveillance using reliable high throughput methodologies.
From our data, the enrichment approach increased the
proportion of reads mapping to C. trachomatis, enabling
full length genomes to be extracted from 80% of theclinical samples without prior genome amplification. This
compares favourably with the recovery of only a partial C.
trachomatis genome from a single vaginal swab sample in
a previous study and full genomes from 15-30% clinical
samples after genome amplification in another study
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http://www.biomedcentral.com/1471-2334/14/591[39,18]. The limit of detection has previously been iden-
tified to a diagnostic Ct-value of 23.1, when generating
complete genomes directly from clinical samples [18].
Our whole-genome enrichment generated a full consensus
genome from a vaginal swab sample with approximately
552,000 genome copies (~6,500 copies/μl and Ct-value of
27) and from a urine sample with approximately 33,000
genome copies (~400 copies/μl and Ct-value of 31). Im-
portantly the whole-genome enrichment method did not
add mutagenic bias to the sequence data. The bait set,
which was designed from known C. trachomatis genomes
retrieved from GenBank, enriched for C. trachomatis from
both biovars and from 10 distinct ompA serovars. The se-
quencing read depth was independent of ompA serovar,
but related to input genome copy number with the two
vaginal swab samples that failed to generate full genomes,
falling below the current technical threshold of ~552,000
genome copies per enrichment reaction. However, for low
titre samples containing <552,000 genome copies, we were
able to generate complete plasmid sequences. Finally our
data confirm that whole-genome enrichment did not alter
the consensus sequence, with high sequence identity be-
tween a enriched and un-enriched cultured sample.
We found that recovery of genomes from urine is more
efficient than from vaginal swabs, a finding that is ex-
plained by the high complexity of vaginal swabs containing
large amounts of contaminating DNA from the natural
microbiota and the host. This explanation is supported by
the finding that reads mapping to the rRNA genes were
overrepresented in the vaginal swabs (see coverage plot in
Additional file 1) and that these reads also showed hom-
ology (identified by BLASTn search) to 16S rRNA in
Lactobacillus iners and Lactobacillus cripatus, both com-
monly found as part of the vaginal microbiota [41]. Whole-
genome enrichment of C. trachomatis from vaginal swabs
also enriched a highly conserved region from the tufA gene
homologous to Mobiluncus and Mycoplasma hominis both
found in the vaginal microbiota and which have been asso-
ciated with bacterial vaginosis (BV) [42,43]. In contrast,
only one of the three urine C. trachomatis sequences (all
urine samples were from male patients) showed contamin-
ation within this conserved region of the tufA gene. Here
the contaminant showed homology to Lactobacillus casei
(identified by BLASTn search), which is a known bacteria
that can be found in the human gut [44]. L. casei can also
colonize the vagina when the normal vaginal microbiota is
disrupted [45] and will therefore also be a potential con-
taminant in sequences obtained from vaginal swab samples.
This, together with the fact that we recovered <1% se-
quence reads mapping to C. trachomatis from the two low
copy number samples that failed to generate complete ge-
nomes, underlines the need for further optimisation both
technically and computationally to screen out contamina-
ting sequences.Generation of WGS is useful for understanding the
evolution of C. trachomatis antimicrobial resistance, an
area of increasing importance for the management of
sexually transmitted bacteria. None of the subjects from
whom we obtained samples had evidence of resistant
bacteria. Nonetheless, the identification of three fixed
SNPs in the L22 gene from sample CT-36, which have
been associated with macrolide resistance when in com-
bination with two mutations in the 23S rRNA gene [33],
highlights the potential use of WGS of C. trachomatis
for stratification of treatment options. In this case avoid-
ing treatment with macrolides would potentially reduce
the chance of acquiring 23S rRNA mutations and, con-
sequently, macrolide resistance. Putative C. trachomatis
antimicrobial resistance is postulated to arise from hetero-
geneous populations [7]. Alternatively, compartmentalisa-
tion of bacteria with some being exposed to antimicrobials
and becoming resistant while others are sequestered and
remain unexposed and sensitive, would produce a similar
outcome. Because of the high read depth generated, next
generation sequencing methods provide an opportunity to
interrogate variant data, including the presence of low-
level resistance mutations. We have previously shown,
using a highly heterogeneous herpesvirus vaccine, that
for allele frequencies >1%, whole-genome enrichment
methods do not change the population structure [20]. For
sample CT-33 where the mean read depth was >400×, we
found 870 variant sites of which more than 86% were
present at frequencies ≤5%. Of the 27 synonymous and 6
non-synonymous single nucleotide variants that occurred
at frequencies >5%, 18 synonymous mutations were found
to be due to contaminating tufA gene sequences from
other microorganisms present in the natural microbiota
and 15 being due to C. trachomatis mutations. Four non-
synonymous variant sites were found to be natural poly-
morphisms, as the variants were fixed in some genomes
but not in others. Our findings raise the possibility that
these positions are heterogeneous in vivo. However, since
most available sequences for this region are from cultured
isolates, which are much less heterogeneous, sequencing of
more clinical specimens is needed. None of the 15 con-
firmed variant sites were located in genes that have been
associated with antimicrobial resistance. However, the low
background variation could offer the opportunity for easy
identification of heterogeneous resistance mutations from
variant read data and this will be explored further with
suitable sample sets.
Conclusions
We have shown that novel whole-genome enrichment
increase the sensitivity by >10-fold when performing
WGS of C. trachomatis directly from clinical specimens.
The method is fully automatable and provides the poten-
tial for high-throughput sequencing of this intracellular
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http://www.biomedcentral.com/1471-2334/14/591bacterium and the generation of large datasets for better
understanding of diversity, evolution and antimicrobial
resistance. The method might be less applicable to bac-
teria exploiting lateral gene transfer as means of evolu-
tion, but has great potential to be applied on other
obligate intracellular or fastidious pathogens with a clonal
population structure.Additional files
Additional file 1: Default parameters using CLC Genomic Workbench –
sample CT-33|D (extracted from a vaginal swab sample) used as
example.
Additional file 2: Recovery of complete plasmid sequence directly
from clinical specimens. All 10 samples were multiplexed and sequenced
twice on a MiSeq in two separate runs, after which the data-sets were
combined.
Additional file 3: Recombination in the ompA gene. The plot illustrates
the similarity of the ompA gene sequence from sample CT-38 to the
ompA gene sequences from each of the clinical samples. Breakpoints
were identified at positions 301 and 967 and are highlighted by the
asterisks.
Additional file 4: Summary of known antimicrobial resistance
mutations in C. trachomatis. Summary of mutations associated with
antibiotic resistance in Chlamydia trachomatis.
Additional file 5: Mutations associated with antimicrobial
resistance identified in one clinical sample (CT-36|E). Mutations
associated with antibiotic resistance identified in sample CT-36|E.
Additional file 6: Non-synonymous and Synonymous Variants
(>0% - <50%). Non-synonymous and synonymous variants in sample
CT-33|D at frequencies between >0% - <50% plotted against position in
the C. trachomatis genome.
Additional file 7: Variants >5% frequency found within one clinical
sample (CT-33|D). Non-synonymous Single Nucleotide Variants >5%
frequency.
Additional file 8: Genome Atlas – comparing SNPs differences
identified in vaginal swabs and urine samples. The genome atlas
illustrates the non-synonymous SNP differences found between eight
clinical Chlamydia trachomatis samples processed with whole-genome
enrichment and the GenBank reference strain F/SW4 (Accession no.
NC_017951.1). The two outer tracks shown in green illustrate the open
reading frames (ORFs) annotated in the reference strain with forward and
reverse orientation respectively. The red tracks show all the non-synonymous
SNP differences found between the vaginal swab samples and the reference
strain. The blue tracks show all the non-synonymous SNP differences found
between the urine samples and the reference strain.
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